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aBstraCt
This is a case report discussing the case of a patient with idiopathic macular telangiectasia type 2. The diagnosis 
and the management of the patient are analysed as well as the possible factors that attribute to the appearance of 
idiopathic macular telangiectasia.
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introduCtion
Macular telangiectasia (MacTel) is a  condition 
of the retina, which leads to abnormalities of cap-
illaries of the fovea or the perifoveal region [1, 2]. 
It is associated with loss of the outer nuclear layers 
and ellipsoid zone that can progress to cystic cavita-
tion-like changes in all retinal layers, development 
of full-thickness macular holes, or subretinal neo-
vascularisation in advanced stages. 
Macular telangiectasia is divided into three cat-
egories [2]: 
•	 MacTel type 1, which is a  congenital form of 
the disease and is unilateral. MacTel type 1 is an 
uncommon form of the disease;
•	 MacTel type 2, which is the most common form 
of the three types. It is acquired and bilateral 
and is more common in middle-aged or older 
patients. There are studies indicating that Mac-
Tel type 2 is more common in female patients;
•	 MacTel type 3 exists but is extremely rare. Patients 
with Type 3 tend to have more vessels diseased, 
causing the blood vessels to become occluded.
Macular telangiectasia type 1 [2] is probably 
best defined as an acquired capillary ectasia and 
dilation in the parafoveal region, leading to vascu-
lar incompetence. The telangiectatic vessels develop 
micro-aneurysms, which subsequently leak fluid, 
blood, and occasionally lipid. Macular telangiecta-
sia type 1 has been described as a variant of Coats’ 
disease, which is defined by extensive peripheral 
retinal telangiectasis, exudative retinal detachment, 
relatively young age of onset, and male predilection. 
The precise aetiology is unknown but it has been 
speculated that chronic venous congestion caused 
by obstruction of the retinal veins as they cross 
retinal arteries at the horizontal raphe may be a con-
tributory factor.
In macular telangiectasia type 2 histopathology 
studies [3, 4] have shown a  loss of Mueller cell 
markers in the clinically altered area, suggesting that 
Mueller cell death may be involved in the patho-
genesis. Due to the relatively recent manifestation 
of MacTel (last 25 years) there is not much in-
formation about the aetiology and the course of 
the disease. Hence there is a  big study underway, 
called the MacTel Project, which is an international 
research collaboration among clinicians and bench 
scientists to study idiopathic macular telangiectasia 
type 2, which the most common of the three forms, 
as mentioned above.
The MacTel project has found a  prevalence of 
diabetes mellitus (28%) and hypertension (52%) in 
MacTel type 2 [2–4]. These facts, combined with 
the age that the disease appears (60 years old or 
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Figure 1. OCT examination of the right eye
above), point toward long-term vascular stress as the 
aetiology of this disease. 
The diagnosis of MacTel is made by ophthal-
mological clinical examination and fundus imag-
ing. Patient history and symptoms [3, 4] might be 
helpful for the diagnosis. Patients with MacTel ty - 
pe 2 complain about metamorphopsia or scotoma. 
As the disease progresses, an increased scotoma can 
be perceived with decreased visual acuity as the con-
dition affects the fovea and perifoveal area. Visual 
acuity in MacTel type 2 usually stays at 20/32 or 
better according to the Mac Tel Project, and it can 
decrease if a macular hole develops. Vision can be 
severely diminished in MacTel type 1 and 3.
Fundoscopically, in MacTel type 2, foveal or peri-
foveal ectatic vessels with possible presence of venules 
diving at a right angle into deeper retinal layers are 
observed [2, 3]. Greyish discoloration of the tem-
poral perifoveal area is the earliest sign. Subretinal 
neovascularisation temporal to the fovea may be seen 
in this disease, and it can be associated with exudates 
or haemorrhage. RPE (Retinal Pigment Epithelium) 
hyperplasia can also be seen at the fovea or temporal 
perifovea. Also, in later stages, pseudolamellar holes 
can develop into full-thickness macular holes.
In optical coherence tomography (OCT) [5, 6], 
temporal foveal pit enlargement due to loss of outer 
nuclear layer and ellipsoid zone that can progress 
into large cysts, which can encompass all retinal 
layers. Hyper-reflective areas [7, 8] on OCT corre-
late to areas of RPE hyperplasia and migration. In 
a fluorescein angiography of a patient with MacTel 
type 2, temporal foveal telangiectatic vessels appear, 
which leak in later stages. Evidence of venules div-
ing at a  right angle into deeper retinal layers can 
also be seen. Subretinal neovascularisation has been 
shown to be retinal in origin because fluorescein 
angiography shows a feeding arteriole and a drain-
ing venule.
Because of the lack of knowledge we have about 
this disease, there is still much to be understood 
about it. Some patients may only need careful mon-
itoring and may not need treatment at all. If the 
blood vessels begin to leak fluid and cause swell-
ing and scarring, laser treatments will help relieve 
the swelling and reduce complication. Steroids are 
sometimes used to minimise [9, 10] inflammation, 
and drugs such anti-VEGF [9–12] (vascular en-
dothelial growth factor) are being used to stop ab-
normal blood vessel growth.
Case report
A 68-year-old female visited the office for examina-
tion, complaining about gradual vision loss over the 
last decade in both eyes. Over the last months she has 
noticed a rapid deterioration of the vision of her right 
eye as well. Her best corrected visual acuity (BCVA) 
was 20/200 on the right eye and 20/30 on her left eye. 
The patient was dilated and Dr Mallias performed 
a thorough fundus examination. The patient was also 
examined with optical coherence tomography (OCT), 
and the findings were the following.
On the right eye, degenerations were observed 
on the fovea and on ISOS (photoreceptors and pig-
ment epithelium complex) along with a cystic space 
on the inner layers of the retina, at the area of the 
fovea (Fig. 1).
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Figure 2. OCT examination of the left eye
Figure 3. Multicolour examination of both eyes
On the left eye, degenerations were observed 
on ISOS parafoveally, along with a  cystic space 
on the inner layers of the retina, at the area of the 
fovea (Fig. 2).
On the multicolour examination (Fig. 3), whit-
ish hyper reflective areas were observed parafoveally 
on both eyes. The above findings are consistent with 
macular telangiectasia type 2 (MacTel type 2). 
disCussion
As already mentioned, MacTel type 2 may be 
the most common of the three types of the disease, 
but the disease is very rare in general. Usually, there 
is not such a dramatic loss of vision, especially in 
cases where a  macular hole has not yet occurred. 
However, in this case, the BCVA on the right eye 
was 20/200 without the existence of a full thickness 
macular hole. That loss of visual acuity on the right 
eye can be explained by the loss of photoreceptors 
on the fovea. What should be noted is that the 
patient did not have a history of diabetes mellitus 
or hypertension in order to (partially) justify the 
appearance of MacTel type 2. This fact leads to the 
assumption that in this case the background of the 
disease was genetic.
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MacTel should be differentially diagnosed from 
diabetic retinopathy or radiation retinopathy. In 
cases of neovascularisation, one should be careful to 
distinguish MacTel from age-related macular degen-
eration. The pseudolamellar holes in the early stages 
that can develop into full-thickness macular holes 
due to MacTel should be differentially diagnosed 
from idiopathic macular holes and lamellar macular 
holes. If these macular holes exist due to MacTel 
then they should not be operated on because the 
outcome will not be optimal.
Photocoagulation was recommended, and re-
mains to date the main treatment. It seems to 
be successful in causing resolution of exudation 
and visual acuity improvement or stabilisation in 
some patients [13, 14]. Photocoagulation should 
be used in order to reduce the chance of pro-
ducing a  symptomatic paracentral scotoma and 
metamorphopsia. Small burns (100–200 μm) of 
moderate intensity in a grid-pattern and on multi-
ple occasions, if necessary, are recommended. It is 
unnecessary to destroy every dilated capillary, and, 
particularly during the initial session of photocoag-
ulation, those on the edge of the capillary-free zone 
should be avoided [14].
In one reported patient with macular telangiec-
tasia type I, a single intravitreal bevacizumab injec-
tion resulted in a marked increase in visual acuity 
from 20/50 to 20/20, with significant and sustained 
decrease in both leakage on fluorescein angiogra-
phy and cystoid macular oedema on OCT up to 
12 months [15]. It is likely that patients with mac-
ular telangiectasia type I  with pronounced macu-
lar oedema from leaky telangiectasis may benefit 
functionally and morphologically from intravitreal 
anti-VEGF injections, but this needs to be further 
investigated. 
The use of vascular endothelial growth factor 
(VEGF) inhibitors, which have proven successful in 
treating age-related macular degeneration, have not 
proven to be effective in non-proliferative MacTel 
type 2 [16]. Anti-VEGF reduces the vascular leak 
seen on angiography, although microperimetry sug-
gests that neural atrophy may still proceed in treat-
ed eyes. In proliferative stages (neovascularisation), 
treatment with Anti-VEGF can be helpful.
Triamcinolone acetonide has proven to be ben-
eficial in the treatment of macular oedema by their 
anti-inflammatory effect, their downregulation of 
VEGF production, and stabilisation of the blood 
retinal barrier [17, 18]. However, it is not used fre-
quently due to the side effects (elevated intraocular 
pressure, cataract).
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